Equities

Palatin Technologies Inc

Palatin Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.30
  • Today's Change0.14 / 12.07%
  • Shares traded338.55k
  • 1 Year change-35.00%
  • Beta0.9445
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Palatin Technologies, Inc. share price to rise to 17.00 in the next year from the last price of 1.30.
High1,207.7%17.00
Med1,207.7%17.00
Low1,207.7%17.00

Earnings history & estimates in USD

On Sep 30, 2024, Palatin Technologies, Inc. reported 4th quarter 2024 losses of -0.50 per share. This result exceeded the -0.56 consensus loss of the 2 analysts covering the company and exceeded last year's 4th quarter results by 45.05%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+10.40%
Palatin Technologies, Inc. reported annual 2024 losses of -2.03 per share on Sep 30, 2024.
Average growth rate+1.18%
More ▼

Revenue history & estimates in USD

Palatin Technologies, Inc. had 4th quarter 2024 revenues of 350.00k. None of the 2 analysts following the company expected it to generate revenues. This was 59.77% below the prior year's 4th quarter results.
Average growth rate-27.97%
Palatin Technologies, Inc. had revenues for the full year 2024 of 4.49m. This was 7.50% below the prior year's results.
Average growth rate+316.85%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.